Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Trevi Therapeutics, Inc. (TRVI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.7500-0.0300 (-0.79%)
At close: 04:00PM EDT
3.7000 -0.05 (-1.33%)
After hours: 07:40PM EDT
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended June 30, 2022, as well as provided business updates.

  • PR Newswire

    Trevi Therapeutics to Present at Upcoming August Conferences

    Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences:

  • PR Newswire

    Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30

Advertisement
Advertisement